Almac’s Strengthened Facilities Accommodates Demand of Late Stage API Manufacture

Almac is pleased to report that the expansion of its API manufacturing facilities has allowed significant growth in its late stage manufacturing service.

The facility upgrade included installation of two 1000-L reactors and state-of-the-art pressure filter dryer, which now allows production of highly potent API manufacture up to 500 kg with a dedicated nitrogen jet mill for micronisation.

Denis Geffroy, VP Business Development, commented: “During the past few years, Almac’s API business has continued to grow at a double digit pace. The facility expansion was much needed and the results are already striking with several Phase III and Commercial projects awarded.”

Almac’s clients also leverage Almac’s API and Drug Product integrated offering where API manufacture and finished drug production is done on the same site, ensuring reduction in costs and timelines whilst maintaining scientific continuity. This year Almac has completed its first joint commercial API and Drug Product manufacture, which demonstrated the advantages of integrated operations. 

“Today, our API business is made of 30% late-phase and commercial projects, compared with just 5% 3 years ago, which gives a clear indication that our strategy to invest through expansion was the right one,” added Denis.